SynthesisPloS one2016
Perioperative Use of Clevidipine: A Systematic Review and Meta-Analysis.
Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Comparative Efficacy and Safety of Clevidipine Versus Nicardipine in Hypertensive Emergencies: A Systematic Review and Meta-Analysis.Clinical cardiology · 2026Pooled it
- Clevidipine for the management of hypertension in the perioperative cardiac and noncardiac surgical settings: a systematic review.Frontiers in medicine · 2025Pooled it
- The safety and efficacy of clevidipine for blood pressure management in neurocritical patients: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Blood pressure lowering effect of calcium channel blockers on perioperative hypertension: A systematic review and meta-analysis.Medicine · 2018Pooled it
- Efficacy and safety of Clevidipine for blood pressure control after carotid endarterectomy: a prospective cohort study.Journal of anesthesia, analgesia and critical care · 2026Article
- Clevidipine versus nitroglycerin for blood pressure control during carotid endarterectomy: a cohort study.BMC anesthesiology · 2025Observational
- Pump-driven clinical infusions: laboratory comparison of pump types, fluid composition and flow rates on model drug delivery applying a new quantitative tool, the pharmacokinetic coefficient of short-term variation (PK-CV).Journal of clinical monitoring and computing · 2025Article
- Synthetic Approaches, Properties, and Applications of Acylals in Preparative and Medicinal Chemistry.Molecules (Basel, Switzerland) · 2024Review
- Review
- The Management of Hypertensive Emergencies-Is There a "Magical" Prescription for All?Journal of clinical medicine · 2022Review
- The Current Role of Clevidipine in the Management of Hypertension.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022Review
- High-Risk Perioperative Medications in the Chinese Elderly Population.Clinical interventions in aging · 2021Article
- Observational
- [Austrian Consensus on High Blood Pressure 2019].Wiener klinische Wochenschrift · 2019Article
- Examining the Use of Sodium Nitroprusside in Coronary Artery Bypass Grafting: Is the Benefit Worth the Cost?Hospital pharmacy · 2017Article
- Management of hypertension in patients undergoing surgery.Annals of translational medicine · 2017Article
- Treatment of hypertensive emergencies.Annals of translational medicine · 2017Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClevidipine is an ultrashort-acting drug for rapid reduction of blood pressure by selectively acting on the L-type Ca2+ channels on arteriolar smooth muscle. The drug's ultrashort action in reducing the blood pressure is due to its rapid hydrolysis by blood and extravascular tissue esterases, which does not depend on hepato-renal metabolism and excretion. An analysis of the perioperative management of blood pressure should be considered to compare with other intravenous antihypertensive agents.
methodsAnalyses of the available evidence in randomized clinical trials following the PRISMA methodology as well as clinical significance according to the GRADE system were conducted. Placebo versus other antihypertensive drugs studies were included. Statistical assessments were done using the X2 and I2 tests.
resultsClevidipine was more effective in maintaining the blood pressure within pre-specified ranges compared with other antihypertensive drugs (MD, -17.87 CI 95%: -29.02 to -6.72; p = 0.02). The use of Clevidipine versus placebo and rescue antihypertensive intravenous drug showed a clear reduction in rates of treatment failure (RR 0.10; IC 95%; 0.05-0.18; p <0.0001). There was no difference in the incidence of adverse events compared with placebo (RR 1.47; 95% CI 0.89 to 2.43, p = 0.14) and with other antihypertensive drugs (RR 0.78, 95% CI 0.45 to 1.35; p = 0.37). In addition, there was no difference in the incidence of atrial fibrillation (AF) between clevidipine and control groups (RR 1.09, IC del 95%: 0.65 a 1.83; p = 0.73).
conclusionsClevidipine is an ultrafast-acting drug that is highly effective for management of perioperative arterial hypertension. It is devoid of adverse effects associated with the use of other IV antihypertensives. Its favorable pharmacodynamic and pharmacokinetic properties make clevidipine the drug of choice for the management of acute perioperative hypertension. It is important to emphasize the need for further studies with a larger number of patients to confirm these findings and increase the degree of evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.